background image

The Week Ahead: Japanese election to drive yen, FX volatility, plus eyes on US nonfarm payrolls & inflation, AstraZeneca FY results

Equities 3 minutes to read
Neil Wilson
Neil Wilson

Investor Content Strategist

Your guide to the trading calendar over the festive fortnight covering 9 – 13 Feb.

Note: This is marketing material. This article is not investment advice, capital is at risk.

Equity market volatility rose in recent days as investors reined in some of the most popular momentum trades, pulling back on big tech as fears resurfaced about a bubble in the AI space. Combined Meta, Microsoft, Alphabet and Amazon said they would hike AI capex by around 50% this year to around $650bn. Elsewhere, the FTSE 100 made a record high before pulling back on the wider risk-off moves, we saw continued volatility in precious metals as gold and silver swung around, while crypto markets came under greater pressure with Bitcoin touching $60,000.

Looking ahead, markets will be digesting the outcome of the snap parliamentary elections in Japan over the weekend. A rescheduled US nonfarm payrolls report will be watched extra closely after some signs of weakness in the labour market, while CPI inflation data will be closely monitored. On earnings, the likes of Ford, McDonald’s and Coca-Cola deliver a snapshot of the US consumer, while in AstraZeneca, the largest company on the FTSE, will release full-year results. Sterling will be susceptible to political risk as pressure builds on the prime minister Keir Starmer.

Here’s the key events to watch over the next week.

Monday, February

Japan’s parliamentary elections set the scene for week as markets anticipate a big win for ruling PM Sanae Takaichi. A landslide win for her ruling Liberal Democratic Party in the lower house elections could add to pressure on the yen and JGBs as it’s expected this would free her hand to pursue more reflationary policies and markets fixate on fiscal sustainability. USDJPY could retest the 16line in the sand and there is a chance of ongoing intervention in JPY if the election stokes the 'Takaichi trade' some more. Traders will be particularly keen to hear about the pledge to suspend the 8% sales tax on food, a proposal that triggered the big selloff in Japanese bonds last month.

Fed Governor Christopher Waller, Atlanta Fed President Raphael Bostic, ECB chief economist Philip Lane and BoE rate-setter Catherine Mann are due to speak at various events.

Tuesday, 10 February

AstraZeneca, the largest company on the FTSE by market capitalisation, reports its full-year results. The key focus will be around revenue growth in high value lines, such as Oncology – its largest and fastest growing therapeutics business; as well as Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology (R&I). Investors will also be looking at commentary around new drugs rolling out this year with potential $30bn in peak sales in the pipeline and how these get it to $80bn in annual sale by 2030. Markets anticipate revenues rising 8.4% to $58.6 billion, and a 7.7% rise in operating profit to $18.3 billion. Barclays and BP are also due to report Q4 and full-year results.

In the US, retail sales data provides the main economic release alongside the employment cost index, which an important productivity indicator. Earnings come from Coca-Cola, Spotify, Cloudflare, Ford and Gilead. Cleveland Fed President Beth Hammack and Dallas Fed President Lorie Logan are due to speak.

Wednesday, 11 February

Jobs day at last as traders watch the US jobs report for January, delayed from 6 Feb. The unemployment
rate is expected to hold at 4.4%, with nonfarm payrolls rising about 70,000 for the month against December’s 50,000. The report is extra in focus after the previous week’s Challenger job cuts report that spooked equity markets. It showed January layoffs at the highest level since 2009.

On the earnings front, Kraft Heinz, McDonald’s, Shopify, Cisco Systems, QuantumScape and The Trade Desk are among the US large caps set to report, whilst Barratt Redrow takes the limelight in London. In Europe it’s busy on the corporate calendar with Heineken, Michelin, Dassault and TotalEnergies among the major stocks on the slate.

Thursday,12 February

Ashmore, British American Tobacco, Schroders and Unilever report earnings but the highlight arguably will be RELX, which reports full-year resultsafter a deep selloff in the stock as it was seen as particularly vulnerable to Anthropic’s new AI toolkit. One of itsnew AI tools can automate a lot of legal work, which hurt sentiment on RELX as it owns the LexisNexis legal data analytics service.

In the US, cybersecurity stocks Arista Networks and Palo Alto Networks report earnings, alongside AirbnbPinterest and Twilio. .Keep an eye on earnings from Applied Materials, which supplies equipment, services and software for the manufacture of semiconductor chips.

UK GDP data will be scored for signs of a pickup in activity as evidenced by the latest round of PMI surveys. US weekly unemployment claims are on deck as well following the surprise jump in claims last week at the same time as job openings slipped to a five-year low.

Friday, 13 February

NatWest reports full-year results and we get an earnings update from Moderna. The focus for the wider market will be the US CPI inflation report, which is seen as a key test of whetherinflation is continuing to cool at a gradual pace.Inflation remained steady at 2.7% in December, while the core inflation rate ticked down to 2.6%. However, there are concerns about the quality of the data as it was affected by the government shutdown that lasted from October until November last year. 

 

 

 

Outrageous Predictions 2026

01 /

  • Executive Summary: Outrageous Predictions 2026

    Outrageous Predictions

    Executive Summary: Outrageous Predictions 2026

    Saxo Group

    Read Saxo's Outrageous Predictions for 2026, our latest batch of low probability, but high impact ev...
  • A Fortune 500 company names an AI model as CEO

    Outrageous Predictions

    A Fortune 500 company names an AI model as CEO

    Charu Chanana

    Chief Investment Strategist

    Can AI be trusted to take over in the boardroom? With the right algorithms and balanced human oversi...
  • Dollar dominance challenged by Beijing’s golden yuan

    Outrageous Predictions

    Dollar dominance challenged by Beijing’s golden yuan

    Charu Chanana

    Chief Investment Strategist

    Beijing does an end-run around the US dollar, setting up a framework for settling trade in a neutral...
  • Dumb AI triggers trillion-dollar clean-up

    Outrageous Predictions

    Dumb AI triggers trillion-dollar clean-up

    Jacob Falkencrone

    Global Head of Investment Strategy

    Agentic AI systems are deployed across all sectors, and after a solid start, mistakes trigger a tril...
  • Quantum leap Q-Day arrives early, crashing crypto and destabilizing world finance

    Outrageous Predictions

    Quantum leap Q-Day arrives early, crashing crypto and destabilizing world finance

    Neil Wilson

    Investor Content Strategist

    A quantum computer cracks today’s digital security, bringing enough chaos with it that Bitcoin crash...
  • SpaceX announces an IPO, supercharging extraterrestrial markets

    Outrageous Predictions

    SpaceX announces an IPO, supercharging extraterrestrial markets

    John J. Hardy

    Global Head of Macro Strategy

    Financial markets go into orbit, to the moon and beyond as SpaceX expands rocket launches by orders-...
  • Taylor Swift-Kelce wedding spikes global growth

    Outrageous Predictions

    Taylor Swift-Kelce wedding spikes global growth

    John J. Hardy

    Global Head of Macro Strategy

    Next year’s most anticipated wedding inspires Gen Z to drop the doomscrolling and dial up the real w...
  • Britain’s Great EU Backdoor Return

    Outrageous Predictions

    Britain’s Great EU Backdoor Return

    Neil Wilson

    Investor Content Strategist

    Faced with rolling fiscal, economic, trade and political crises the UK government sneaks back into t...
  • Obesity drugs for everyone – even for pets

    Outrageous Predictions

    Obesity drugs for everyone – even for pets

    Jacob Falkencrone

    Global Head of Investment Strategy

    The availability of GLP-1 drugs in pill form makes them ubiquitous, shrinking waistlines, even for p...
  • Despite concerns, U.S. 2026 mid-term elections proceed smoothly

    Outrageous Predictions

    Despite concerns, U.S. 2026 mid-term elections proceed smoothly

    John J. Hardy

    Global Head of Macro Strategy

    In spite of outstanding threats to the American democratic process, the US midterms come and go cord...

This content is marketing material. 

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Market Ltd. (SCML) provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice or a recommendation.

SCML content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

SCML partners with companies that provide compensation for promotional activities conducted on its platform. Some partners also pay retrocessions contingent on clients investing in products from those partners. 

While SCML receives compensation from these partnerships, all educational and research content remains focused on providing information to clients.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. SCML does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992